5,589 Shares in Guardant Health, Inc. $GH Acquired by Northwestern Mutual Wealth Management Co.

Posted by Francis Steltz on Aug 26th, 2026

Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 5,589 shares of the company’s stock, valued at approximately $839,000.

Several other hedge funds have also added to or reduced their stakes in the stock. Elyxium Wealth LLC purchased a new position in shares of Guardant Health in the 4th quarter worth about $35,000. Parallel Advisors LLC grew its position in Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after purchasing an additional 219 shares during the last quarter. Ascentis Independent Advisors bought a new stake in Guardant Health during the 1st quarter valued at about $38,000. Hollencrest Capital Management bought a new stake in Guardant Health during the 1st quarter valued at about $41,000. Finally, EFG International AG purchased a new position in Guardant Health in the fourth quarter worth about $41,000. 92.60% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, Director Ian T. Clark sold 14,180 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the transaction, the director directly owned 2,975 shares of the company’s stock, valued at $472,787. This represents a 82.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Amirali Talasaz sold 37,500 shares of the firm’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $169.16, for a total value of $6,343,500.00. Following the completion of the transaction, the chief executive officer owned 37,500 shares in the company, valued at approximately $6,343,500. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 549,318 shares of company stock valued at $82,631,933 in the last ninety days. Corporate insiders own 5.60% of the company’s stock.

Guardant Health Stock Up 1.1%

Shares of NASDAQ GH opened at $164.92 on Wednesday. The firm’s 50-day moving average price is $155.33 and its 200-day moving average price is $119.49. The company has a market cap of $22.13 billion, a PE ratio of -47.25 and a beta of 1.60. Guardant Health, Inc. has a 52-week low of $53.40 and a 52-week high of $176.58.

Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million during the quarter, compared to the consensus estimate of $314.23 million. The business’s revenue was up 44.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. As a group, equities research analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Sanford C. Bernstein upped their target price on shares of Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, July 2nd. Stifel Nicolaus raised their price target on shares of Guardant Health from $130.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, July 31st. UBS Group set a $150.00 price objective on shares of Guardant Health in a report on Wednesday, June 24th. Piper Sandler upped their price objective on Guardant Health from $135.00 to $193.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Finally, Mizuho increased their target price on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $183.78.

Read Our Latest Stock Report on GH

Guardant Health Profile

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.